Free tool
FAERS Monitor: Mycobutin
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 050689 or its brand name (Mycobutin, Rifabutin). Reports on generic versions are filed under their own applications.
Reports
2,755
Serious
2,287
83% of reports
Hospitalization
977
Death reported
310
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug interaction270
- drug ineffective268
- off label use223
- nausea171
- pyrexia163
- drug resistance161
- mycobacterium avium complex infection150
- drug intolerance129
- neutropenia120
- immune reconstitution inflammatory syndrome119
- product use in unapproved indication109
- diarrhoea100
- dyspnoea95
- vomiting95
- fatigue89
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 25 |
| 2005 | 25 |
| 2006 | 27 |
| 2007 | 27 |
| 2008 | 29 |
| 2009 | 59 |
| 2010 | 48 |
| 2011 | 59 |
| 2012 | 64 |
| 2013 | 42 |
| 2014 | 26 |
| 2015 | 64 |
| 2016 | 94 |
| 2017 | 99 |
| 2018 | 173 |
| 2019 | 135 |
| 2020 | 152 |
| 2021 | 168 |
| 2022 | 206 |
| 2023 | 297 |
| 2024 | 344 |
| 2025 | 390 |
| 2026 | 202 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,404 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| mycobacterium avium complex infectionSignal | 150 | 451.8 | 384.8 | 63,285 |
| immune reconstitution inflammatory syndromeSignal | 119 | 186.8 | 156.3 | 21,286 |
| drug resistanceSignal | 161 | 48.1 | 41.4 | 7,349 |
| drug interactionSignal | 270 | 13.0 | 11.6 | 3,000 |
| drug intoleranceSignal | 129 | 10.2 | 8.6 | 1,066 |
| neutropeniaSignal | 120 | 6.7 | 5.7 | 584 |
| pyrexiaSignal | 163 | 3.6 | 3.1 | 308 |
| product use in unapproved indicationSignal | 109 | 3.4 | 2.8 | 180 |
| off label use | 223 | 1.9 | 1.7 | 106 |
| nausea | 171 | 1.6 | 1.4 | 45 |
| drug ineffective | 268 | 1.6 | 1.4 | 56 |
| vomiting | 95 | 1.5 | 1.3 | 18 |
| dyspnoea | 95 | 1.3 | 1.1 | 6 |
| diarrhoea | 100 | 1.2 | 1.0 | 3 |
| fatigue | 89 | 0.9 | 0.7 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.